RETRACTED: Dominant suppression of inflammation by glycan-hydrolyzed IgG

Abstract

The authors wish to note the following: "Using studies of IgG hydrolyzed by the streptococcal glycan hydrolyzing enzyme EndoS, we found that treatment of mice with hydrolyzed IgG blocked antibody mediated arthritis. As an explanation for this observation, we suggested that EndoS-hydrolyzed IgG per se dominantly blocks local immune complex formation."With new data from our own follow up experiments, we have now found that this conclusion was incorrect."Our new data shows that injection of EndoS is much more potent in vivo than we could logically anticipate, as i.v. injection of doses containing less than 0.1 μg EndoS mixed with IgG suppressed arthritis using the same model as the one reported in the initial paper (collagen antibody-induced arthritis). We previously excluded the possibility that contaminating EndoS could play a role, as this contaminating amount was not detected using standard methods in the hydrolyzed IgG fraction we used in the experiments. Furthermore, much higher doses of EndoS injected in the same mouse strain as a control experiment did not affect collagen induced arthritis in earlier experiments. The correct interpretation of our collective data is that EndoS operates very potently in vivo on an immune complex-mediated disease, possibly by accumulating within immune complexes.

Profiling IgG N-glycans as potential biomarker of chronological and biological ages

“…Many epidemiological studies and experimental observations have demonstrated that changes in IgG Fc glycosylation induce pro-inflammatory or anti-inflammatory actions of Igs, [ 10 , 20 , 39 , 40 ] indicating that IgG Fc glycosylation plays an important role in the process of aging. [ 29 , 41 ] The reduction of terminal galactose residues was suggested as a mechanism to enhance the pro-inflammatory activity in vitro.…”

Fragments of Bacterial Endoglycosidase S and Immunoglobulin G Reveal Subdomains of Each That Contribute to Deglycosylation

“…EndoS has been successful in in vivo studies for the treatment of model systems of rheumatoid arthritis, experimental glomerulonephritis, and systemic lupus erythematosus (11, 15–17). …”

Glycosylation of Recombinant Anticancer Therapeutics in Different Expression Systems with Emerging Technologies

“…Therefore, GlycoDelete technology favors production of antibodies when the case is neutralization of antigen rather than additional effector function. Likewise, the reduced N-glycanprotocol is important in the biopharmaceutical industry, and the benefits of short N-glycans have also been reported (160)(161)(162).…”